PHARMACY

MannKind Corp. submits NDA for diabetes medication

BY Allison Cerra

VALENCIA, Calif. MannKind Corp. announced Monday that it is requesting approval from the FDA for a new diabetes medication.

The new drug application for Afresa (insulin monomer human [rDNA origin]) Inhalation Powder and the Afresa Inhaler is designed to treat adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.

MannKind explained that Afresa features a pharmacokinetic profile, which mimicks the release of meal-time insulin observed in healthy individuals. The drug reaches peak insulin levels within 12 to 14 minutes of administration.

The NDA submission is based on an extensive clinical program, involving 44 completed studies and five ongoing studies at the time of submission. The clinical program included over 5,300 patients. More than 2,450 subjects with type 1 or type 2 diabetes were randomly assigned to treatment with Afresa in the pooled controlled Phase 2/3 clinical studies. In addition, the clinical pharmacology program included more than 450 subjects exposed to Afresa in single-dose studies.

The extent of exposure meets the current guidance from the FDA regarding the development of therapies for the treatment of diabetes.

“We are delighted to have reached this important milestone,” said Alfred Mann, chairman and CEO, MannKind. “This NDA submission is the culmination of years of clinical research that has supported our long-held belief that Afresa will be a first-in-class ultra rapid-acting insulin with the potential to change the way diabetes is treated.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

CV Therapeutics’ board of directors rejects Astellas’ tender offer

BY Allison Cerra

PALO ALTO, Calif. The board of directors of CV Therapeutics announced Friday it has rejected Astellas’ tender offer of $16 per share.

CV Therapeutics’ determined that the offer “undervalues the company and is not in the best interests of its stockholders”, according to a release.

The announcement comes once day after Gilead Sciences announced it would acquire CV Therapeutics, making it a wholly owned subsidiary of Gilead. The transaction is valued at approximately $1.4 billion, with a tender offer of $20 per share.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Take Care Health Systems opens new clinic in Phoenix

BY Antoinette Alexander

CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has opened a new clinic in the Phoenix market, the clinic operator announced on Friday.

With the new opening, the company now has 18 clinics in that market.

Take Care Health Systems operates a total of 339 clinics in 35 markets throughout 19 states.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?